Peer-influenced content. Sources you trust. No registration required. This is HCN.

Addiction ProfessionalXylazine Crisis: 6 Things Treatment Providers Should Know

Understanding Xylazine: The Rising Challenge in Opioid Crisis Management


As physicians, it’s crucial to stay informed about emerging drug threats. Xylazine, a powerful livestock tranquilizer mixed into fentanyl, is one such threat that’s gaining momentum.

  • Xylazine, a fentanyl add-on, was recently declared an emerging threat by the ONDCP.
  • First documented in toxicology reports in 2006, xylazine contributed to over 30% of fatal heroin and/or fentanyl overdoses in Philadelphia in 2019.
  • Xylazine is now present in 48 of 50 states, with overdose deaths linked to the drug seeing a significant increase across the country.
  • Detection of xylazine is challenging due to the lack of specific lab tests and its covert use mixed into other drugs.
  • Xylazine does not respond to naloxone treatment, necessitating additional interventions in cases of overdose.
  • Xylazine use in humans leads to severe, necrotic flesh wounds and signs of heavy sedation.
  • Physicians can aid in combating this crisis by reporting suspected cases of xylazine use, symptoms, and overdoses to the DEA.
The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form